Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3546210 | 0.84 | CACNA1H (0.37) | KDM4EALDH1A1LMNAMAPTPTK2B | |
| SCHEMBL3555724 | 0.78 | L3MBTL1 (0.38) | KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL3545508 | 0.75 | ATM (0.33) | KDM4EALDH1A1LMNA | |
| SCHEMBL3552893 | 0.74 | ALDH1A1 (0.35) | KDM4EALDH1A1LMNAMAPTPTK2B | |
| SCHEMBL3552851 | 0.71 | POLB (0.35) | MAPT | |
| SCHEMBL26099247 | 0.70 | RET (0.47) | KDM4EALDH1A1LMNAMAPTPTK2B | |
| SCHEMBL3545537 | 0.66 | L3MBTL1 (0.41) | KDM4EALDH1A1 | |
| SCHEMBL4012731 | 0.66 | ALDH1A1 (0.36) | KDM4EALDH1A1LMNAMAPTPTK2B | |
| SCHEMBL2657327 | 0.65 | ALDH1A1 (0.38) | KDM4EALDH1A1LMNAMAPTPTK2B | |
| Hydrochloric Acid SCHEMBL28343857 | 0.65 | ALDH1A1 (0.35) | KDM4EALDH1A1LMNAMAPTPTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1828169-A2 | UREA INHIBITORS OF MAP KINASES | Locus Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060167247-A1 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| WO-2006062982-A2 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167247-A1 | Urea inhibitors of MAP kinases | MAPK1, MAP3K1, MAP3K20 | KDM4E 1734/4885ALDH1A1 2027/4885LMNA 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.